Chan Beals

Hoofd Techniek/Wetenschap/O&O bij Abide Therapeutics, Inc.

Health Technology

Finance

Actieve functies van Chan Beals

Bedrijven	Functie	Begin	Einde
Abide Therapeutics, Inc. Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.	Hoofd Techniek/Wetenschap/O&O	06-01-2016	-

Massachusetts Institute of Technology

Undergraduate Degree

Internationaal

Verenigde Staten

Operationeel

Chief Tech/Sci/R&D Officer	1
Undergraduate Degree	1

Sectoraal

Health Technology	2
Finance	2

Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Bedrijven in privébezit	1
Abide Therapeutics, Inc. Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.	Health Technology

Bedrijven in privébezit

Health Technology